Papaneri Amy B, Johnson Reed F, Wada Jiro, Bollinger Laura, Jahrling Peter B, Kuhn Jens H
Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
Expert Rev Vaccines. 2015 Jul;14(7):949-62. doi: 10.1586/14760584.2015.1036033. Epub 2015 Apr 11.
The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates the in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.
中东呼吸综合征（MERS）最近的出现凸显了研发新方法以加速针对新发疾病的疫苗开发的必要性。然而，有几个障碍阻碍了可获许可的MERS疫苗的研发。首先，缺乏适用于MERS的动物模型使候选疫苗的体内测试变得复杂。其次，由于MERS病例数量较少，制药公司几乎没有动力去生产MERS疫苗，因为临床试验成本很高。此外，从实验室研究到获批疫苗使用的时间线为10年或更长。使用新方法和成本节约策略，可以快速且经济高效地生产基因工程疫苗。随着MERS动物模型开发的进展，这些障碍可以被规避或至少得到缓解。
Zotero 插件
